A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

(MENAFN- GlobeNewsWire - Nasdaq) Explore the GLP-1R agonists market, uncovering new opportunities for repurposing beyond type 2 diabetes and obesity ... Novo Nordisk and Eli Lilly and potential ...

70. Shares of Eli Lilly dropped in pre-market trading Thursday, as competitor Novo Nordisk secured a major win on insurance coverage of its obesity drug and as Lilly reported first-quarter ...

In December of last year, Eli Lilly directly compared the weight ... and that Zeb Bound is expected to soon seize the lead in the obesity market. There are analyses suggesting that Zeb Bound's ...

I believe orforglipron’s approval should finally lead to widespread and global availability of obesity medicines ... improve Eli Lilly’s leadership position in this market and these results ...

Eli Lilly & Co ... Type 2 diabetes and obesity in pill form. The last time the stock rose as much was June 29, 2000, when it closed up 17.7%, according to Dow Jones Market Data.

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap ... on new branded obesity scripts ...

Shares in Eli Lilly rose sharply in pre-market trading today after the company ... an oral alternative to current injectable drugs for obesity. The results from the ACHIEVE-1 study – one of ...

Thanks to these recent developments, Eli Lilly could take the lead in this fast-growing market. The company's ... obstructive sleep apnea in adults with obesity. In November, it announced it ...